# A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

> **NCT06195228** · PHASE4 · RECRUITING · sponsor: **Fudan University** · enrollment: 800 (estimated)

## Conditions studied

- Advanced Thyroid Cancer Patients Who Received Target Therapy

## Interventions

- **DRUG:** dabrafenib plus trametinib with or without PD-1 antibody
- **DRUG:** entrectinib or larotrectinib with or without anti-PD-1 antibdoy
- **DRUG:** pralsetinib or selpercatinib with or without anti-PD-1 antibdoy
- **DRUG:** anlotinib or anlotinib plus anti-PD-1 antibody
- **DRUG:** lenvatinib plus anti-PD-1 antibody
- **DRUG:** Other Targets: precise treatment based on the target

## Key facts

- **NCT ID:** NCT06195228
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-01-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2025-08-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06195228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06195228, "A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT06195228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*